FRANKFURT--The following is a summary of analysts' forecasts for
GlaxoSmithKline plc (GSK) fourth-quarter results, based on a poll
of 12 analysts conducted by Dow Jones Newswires (figures in million
pound, EPS, dividend and target price in pence, according to IFRS).
Earnings figures are scheduled to be released February 4.
===
Core Core Core
Turnover operat. Pretax Net attrib. Core
4th Quarter total profit profit profit EPS
AVERAGE 6,151 1,833 1,660 1,244 26
Prev. Year 6,700 2,020 1,876 1,393 29
+/- in % -8.2 -9.3 -12 -11 -10
MEDIAN 6,182 1,808 1,652 1,232 26
Maximum 6,273 2,054 1,757 1,320 29
Minimum 5,966 1,737 1,584 1,198 25
Amount 12 12 9 8 12
Baader-Helvea 6,101 1,800 1,652 -- 26
Barclays 6,223 1,788 1,636 1,229 26
Berenberg 6,074 1,772 1,625 1,209 25
Bernstein 6,273 1,915 1,757 1,309 27
Cowen and Company 6,185 1,819 1,668 1,253 26
Deutsche Bank 6,235 1,767 1,629 1,200 25
Exane BNP Paribas 5,966 1,808 -- -- 26
J.P. Morgan 6,045 1,737 1,584 1,198 25
Jefferies 6,183 1,897 1,719 1,320 28
Kepler Cheuvreux 6,151 2,054 -- -- 29
Morgan Stanley 6,180 1,830 1,671 1,234 26
UBS 6,196 1,808 -- -- 25
Target price Rating DPS 2014
AVERAGE 1.480 positive 2 AVERAGE 80
Prev. Quarter 1.486 neutral 6 Prev. Year 78
+/- in % -0.4 negative 3 +/- in % +2.6
MEDIAN 1.530 MEDIAN 80
Maximum 1.700 Maximum 80
Minimum 1.250 Minimum 80
Amount 9 Amount 6
Baader-Helvea 1.530 Hold --
Barclays 1.700 Overweight 80
Berenberg 1.620 Hold 80
Cowen -- Marketperform --
Deutsche Bank 1.300 Hold 80
Exane BNP Paribas 1.330 Underperform 80
J.P. Morgan -- Underweight --
Jefferies 1.350 Hold --
Kepler Cheuvreux 1.540 Hold --
Morgan Stanley 1.700 Overweight 80
UBS 1.250 Sell 80
===
Year-earlier figures are as restated by the company.
DJG/voi
Subscribe to WSJ: http://online.wsj.com?mod=djnwires